Litcius/Paper detail

LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial

Jean Bourhis, Yungan Tao, Xiaonan Sun, Clément Sire, Laurent Martin, X. Liem, A. Coutte, Y. Pointreau, Juliette Thariat, J. Miroir, F. Rolland, M.-C. Kaminsky, Christian Borel, Aline Maillard, Laura Sinigaglia, J. Guigay, E. Saâda-Bouzid, C. Even, A. Aupérin

2021Annals of Oncology83 citationsDOI

Topics & Concepts

CetuximabMedicineInternal medicineAvelumabCisplatinClinical endpointOncologyRadiation therapyChemoradiotherapyRandomized controlled trialHead and neck cancerChemotherapyCancerNivolumabImmunotherapyColorectal cancerLung Cancer Research StudiesPeptidase Inhibition and AnalysisHead and Neck Cancer Studies
LBA35 Avelumab-cetuximab-radiotherapy versus standards of care in patients with locally advanced squamous cell carcinoma of head and neck (LA-SCCHN): Randomized phase III GORTEC-REACH trial | Litcius